Nephro Care India’s shares debuted impressively on the NSE SME, opening at ₹171, which is a 90% premium over the IPO price of ₹90. This strong opening reflects significant investor enthusiasm following the IPO’s robust reception.
Nephro Care India’s IPO garnered substantial demand, being oversubscribed 715.78 times overall. Breakdown: Retail Investors at 634.12 times, QIBs at 245.14 times, and NIIs reaching an exceptional 1,787.19 times subscription rate, indicating broad and deep market interest.
Nephro Care India Limited, established in 2014 in Kolkata by Dr. Pratim Sengupta, specializes in renal care, offering dialysis and a broad range of medical services. The company operates a dialysis unit, plans to expand a hospital into a 100-bed multi-specialty facility, and provides comprehensive healthcare services including home dialysis.
Nephro Care India Ltd aims to use IPO funds and internal accruals to establish the “Vivacity Multi Specialty Hospital” in Kolkata, enhancing regional healthcare with a 100-bed facility and specialised services.